It also highlights the rare metastatic behavior of IDH-mutant astrocytomas (previously classified as secondary glioblastomas) and emphasizes the need for long-term monitoring and individualized treatment strategies to improve outcomes. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).